Drugs & Targets FDA issues CRL for rivoceranib + camrelizumab as a first-line treatment for unresectable or metastatic HCC July 17, 2026Vol.52 No.28
Cancer Policy FDA halts public release of Complete Response Letters, following citizen petition July 10, 2026Vol.52 No.27By Claire Marie Porter
Cancer Policy FDA proposes rule to hold foreign tobacco companies to U.S. standards July 10, 2026Vol.52 No.27By Claire Marie Porter
Cancer Policy FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes July 02, 2026Vol.52 No.26By Sara Willa Ernst
Drugs & Targets FDA approved 17 new cancer treatments in 2025, OCE annual report states July 02, 2026Vol.52 No.26
Drugs & Targets FDA approves expanded use of Casgevy for pediatric sickle cell disease or transfusion-dependent beta thalassemia July 02, 2026Vol.52 No.26
Podcast Breaking down Operation Trailblazer: Rolling INDs, outside expert submission help, and one-trial requirement July 01, 2026
Cancer Policy FDA advisory panel recommends first-of-its-kind mRNA flu vaccine for older adults June 26, 2026Vol.52 No.25By Claire Marie Porter
